Targeted Hemostasis in the SICU

This episode is an overview of coagulation disorders and their management within surgical and intensive care settings. It examines the distinction between congenital conditions, such as hemophilia and von Willebrand disease, and acquired defects stemming from trauma, sepsis, or organ failure. The authors highlight how physiological stressors like acidosis and hypothermia exacerbate bleeding, while also addressing the complexities of anticoagulant reversal. Modern diagnostic tools, including thromboelastography, are presented alongside therapeutic strategies involving blood component therapy and pharmacological interventions like tranexamic acid. Ultimately, the source emphasizes a systematic clinical approach to stabilizing patients by balancing rapid hemorrhage control with precise hematologic support. The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns. Targeted Hemostasis in the SICU This guide synthesizes critical information regarding the pathophysiology, diagnosis, and management of bleeding and coagulation disorders encountered in surgical and trauma intensive care settings. I. Historical Context and Evolution of Therapy The effective management of hemorrhage is a relatively modern development in medical history. Key milestones include: Discovery of Blood Types: Karl Landsteiner identified types A, B, and O in 1900, followed by Decastello and Sturli identifying type AB in 1902.Establishment of Blood Banking: The first blood bank in the United States was established in 1937.Technological Advances: The development of crossmatching, anticoagulation, storage techniques, plastic bags, and plasmapheresis eventually enabled component therapy, allowing for the targeted replacement of specific blood elements. II. Congenital Bleeding Disorders Von Willebrand Disease (vWD) As the most common inherited bleeding disorder, vWD results from a deficiency or dysfunction of von Willebrand factor (vWF), which is essential for platelet adhesion and factor VIII stabilization. Type 1: A quantitative deficiency of vWF.Type 2 (2a and 2b): Qualitative functional defects in vWF.Type 3: Complete absence of vWF.Diagnosis: Supported by prolonged partial thromboplastin time (PTT), reduced vWF antigen (in Types 1 and 3), and abnormal ristocetin cofactor assays.Therapy: DDAVP: Stimulates vWF/Factor VIII release; used in Type 1 and 2a; contraindicated in Type 2b.Factor VIII vWF Concentrates: Preferred for Types 2 and 3, or non-responsive Type 1.Cryoprecipitate: Third-line therapy due to lack of virus inactivation.Adjuvants: Antifibrinolytic amino acids (aminocaproic acid and tranexamic acid). Hemophilia A and B Both are X-linked disorders primarily expressed in males. Hemophilia A (Factor VIII Deficiency): Clinical severity is linked to factor levels: mild (>30%), moderate (1%–5%), and severe (<1%). Treatment involves recombinant factor VIII. Recombinant activated factor VIIa (rFVIIa) is used if the patient develops "inhibitors" (IgG antibodies).Hemophilia B (Factor IX Deficiency/Christmas Disease): Clinically similar to Hemophilia A. Treatment utilizes recombinant factor IX concentrates. Inhibitor development is less common (1%) than in Hemophilia A. III. Acquired Bleeding Disorders in the ICU Coagulopathy of Trauma This condition results from a complex interaction between hemorrhagic shock and tissue injury. Tissue ischemia and injury trigger systemic anticoagulation and hyperfibrinolysis via the activation of protein C and the release of tissue plasminogen activator (tPA). Resuscitation efforts can exacerbate this through dilution, acidosis, and hypothermia. Disseminated Intravascular Coagulation (DIC) DIC is a syndrome of systemic intravascular activation of coagulation resulting in fibrin deposition in the microvasculature. Primary Causes: Sepsis (most common), trauma, malignancy, and liver failure.Phenotypes: It may manifest as a thrombotic disorder (common in sepsis) or a consumptive bleeding disorder (fulminant DIC).Diagnosis: The International Society on Thrombosis and Haemostasis (ISTH) scoring system uses platelet count, fibrin markers (D-dimer), PT prolongation, and fibrinogen levels. D-dimer is the most sensitive test.Treatment: Focuses on addressing the underlying disease. FFP and platelets are used for active bleeding. Heparin-Induced Thrombocytopenia (HIT) HIT is an immune-mediated reaction (IgG antibodies to platelet factor IV complex) that causes paradoxical thrombosis rather than bleeding. Clinical Signs: Venous or arterial thromboses (pathognomonic "white clots") and skin necrosis.Diagnosis: Assessment via the 4Ts score or HEP score, followed by ...